Uncontrolled and Resistant Hypertension: From Guideline Updates to RAAS Mechanisms

Description

Learner Objectives

Upon completion of this activity, you should be able to:

Apply updated guideline and expert consensus recommendations to evaluate and manage uncontrolled and resistant hypertension. 
Describe the role of the renin-angiotensin-aldosterone system (RAAS) in hypertension pathophysiology and treatment resistance across common comorbidities

Program Committee and Faculty Disclosures

Planning Committee:
Dave Dixon, PharmD, BCACP, CLS, FACC
American College of Cardiology
Disclosure
Consultant Fees/Honoraria: Innovation Horizons

Joseph Ebinger, MD, FACC
American College of Cardiology
Disclosure
Research/Research Grants: Edwards LifeSciences
Consultant Fees/Honoraria: Edwards LifeSciences

Eileen Handberg, PhD, ANRP, FACC
American College of Cardiology
Disclosure
Consulting Fees/Honoraria: Preventative Cardiovascular Nurses Association

Eugene Yang, MD, MS, FACC
American College of Cardiology
Disclosure
Consulting Fees/Honoraria: Idorsia, Kestra, Sky Labs

Faculty:
Dave Dixon, PharmD, BCACP, CLS, FACC
American College of Cardiology
Disclosure
Consultant Fees/Honoraria: Innovation Horizons

Joseph Ebinger, MD, FACC
American College of Cardiology
Disclosures
Research/Research Grants: Edwards LifeSciences
Consultant Fees/Honoraria: Edwards LifeSciences

Grant Acknowledgement
Educational grant support for this activity provided by AstraZeneca.

Summary

Availability:

On-Demand

Access expires on Oct 16, 2027

Cost:

FREE

Credit Offered:

0.5 CME Credit

0.5 CNE Credit

0.5 AAPA Credit

0.5 ABIM-MOC Point

0.5 IPCE Credit